Breaking Finance News

Vetr Inc. disclosed Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), raising its target price to $14.00 today

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) had its target bumped up to $14.00 by Vetr Inc. in a report released 9/29/2016. The raised target suggests a potential upside of 0.14% based on the company's previous stock price.

On 09/19/2016, Vetr Inc. released a statement about Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) upped the target price from $0.00 to $14.00 that suggested an upside of 0.09%.

Having a price of $12.30, Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) traded -4.87% lower on the day. With the last stock price up 7.97% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SCMP has recorded a 50-day average of $11.95 and a two hundred day average of $11.39. Trade Volume was down over the average, with 258,716 shares of SCMP changing hands under the typical 313,777

Recent Performance Chart

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

Sucampo Pharmaceuticals, Inc. has PE ratio of 43.16 with a one year low of $9.59 and a one year high of $22.11 and has a market capitalization of $0.

A total of 9 firms have reported on Sucampo Pharmaceuticals, Inc.. One equity analyst rating the company a strong buy, 4 brokerages rating the stock a buy, 4 firms rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $20.67.

General Company Details For Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *